Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
DA-1229
metformin
DA-1229 + metformin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Age between 20 to 45, healthy male subjects(at screening)
- Body weight between 55kg - 90kg, BMI between 18.0 - 27.0
- FPG 70-125mg/dL glucose level(at screening)
- Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.
Exclusion Criteria:
- Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder)
- Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery(appendectomy, hernioplasty are excluded)
- Subject who had drug(Aspirin, antibiotics) hypersensitivity reaction
- Subject who already participated in other trials in 2 months
- Subject who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion in 1 months currently.
Sites / Locations
- Clinical Trial Center, Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Arm Label
D → M → D+M
D → D+M → M
M → D → D+M
M → D+M → D
D+M → M → D
D+M → D → M
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
D : DA-1229 5mg qd, M : metformin 1000mg bid
D : DA-1229 5mg qd, M : metformin 1000mg bid
D : DA-1229 5mg qd, M : metformin 1000mg bid
D : DA-1229 5mg qd, M : metformin 1000mg bid
D : DA-1229 5mg qd, M : metformin 1000mg bid
Outcomes
Primary Outcome Measures
AUCτ,ss of DA-1229 and metformin
Cmax,ss of DA-1229 and metformin
Secondary Outcome Measures
Full Information
NCT ID
NCT01941199
First Posted
September 9, 2013
Last Updated
November 25, 2013
Sponsor
Dong-A Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT01941199
Brief Title
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
Official Title
A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 5 mg and Metformin IR 1000 mg After Oral Administration in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dong-A Pharmaceutical Co., Ltd.
4. Oversight
5. Study Description
Brief Summary
This is a randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of DA-1229 5 mg and Metformin IR 1000 mg after oral administration in healthy male volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
D → M → D+M
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Arm Title
D → D+M → M
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Arm Title
M → D → D+M
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Arm Title
M → D+M → D
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Arm Title
D+M → M → D
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Arm Title
D+M → D → M
Arm Type
Experimental
Arm Description
D : DA-1229 5mg qd, M : metformin 1000mg bid
Intervention Type
Drug
Intervention Name(s)
DA-1229
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Type
Drug
Intervention Name(s)
DA-1229 + metformin
Primary Outcome Measure Information:
Title
AUCτ,ss of DA-1229 and metformin
Time Frame
up to 168h
Title
Cmax,ss of DA-1229 and metformin
Time Frame
up to 168h
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age between 20 to 45, healthy male subjects(at screening)
Body weight between 55kg - 90kg, BMI between 18.0 - 27.0
FPG 70-125mg/dL glucose level(at screening)
Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.
Exclusion Criteria:
Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder)
Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery(appendectomy, hernioplasty are excluded)
Subject who had drug(Aspirin, antibiotics) hypersensitivity reaction
Subject who already participated in other trials in 2 months
Subject who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion in 1 months currently.
Facility Information:
Facility Name
Clinical Trial Center, Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects
We'll reach out to this number within 24 hrs